MarketCap
Halozyme Therapeutics HALO
$ 113.9
2.47%
Facebook
X
Telegram
Halozyme Therapeutics Operating Income | HALO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Halozyme Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 469 M | 551 M | 338 M | 268 M | 276 M | 144 M | -67.6 M | -69.3 M | 81 M | -83.2 M | -27.5 M | -63 M | -80.4 M | -53.6 M | -19.8 M | -54.3 M | -58.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 551 M | -83.2 M | 91.1 M |
Quarterly Operating Income Halozyme Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 288 M | 185 M | 218 M | 202 M | 142 M | - | 163 M | 117 M | 95.5 M | - | 88.3 M | 94.5 M | 53.8 M | - | 83.3 M | 34.1 M | 75.7 M | - | 75.6 M | 93 M | 50.7 M | - | 40.3 M | 29.6 M | -3.22 M | - | -24.5 M | -14 M | 2.97 M | - | -25.5 M | -20.1 M | -23.7 M | - | 8.08 M | -25.5 M | -27.5 M | - | -22.7 M | -21.7 M | -16.2 M | - | -23.2 M | 4.23 M | -13.9 M | - | -19 M | -14.9 M | -25.2 M | - | -18.5 M | -22.1 M | -18.5 M | - | -20 M | -14 M | -15.1 M | - | 5.15 M | 3.1 M | -9.66 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 288 M | -27.5 M | 36.5 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
32.3 M | $ 51.0 | 1.83 % | $ 1.48 B |  USA |
 |
Allakos
ALLK
|
-122 M | - | - | $ 28.6 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
12.5 M | $ 1.88 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
-52.7 M | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-77.5 M | - | - | $ 401 M | USA |
 |
Evelo Biosciences
EVLO
|
-108 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
409 M | $ 60.26 | 0.06 % | $ 11.6 B | USA |
 |
BioNTech SE
BNTX
|
-1.4 B | $ 98.52 | 0.24 % | $ 23.8 B |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 2.17 | 0.46 % | $ 3.57 M |  Israel |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-98.4 M | - | - | $ 384 M |  Britain |
 |
Genocea Biosciences
GNCA
|
-52.1 M | - | -15.0 % | $ 3.04 M | USA |
 |
Catalyst Biosciences
CBIO
|
11.5 M | $ 13.99 | 0.84 % | $ 1.25 B | USA |
 |
C4 Therapeutics
CCCC
|
-115 M | $ 2.98 | 0.3 % | $ 247 M | USA |
 |
Codexis
CDXS
|
-41.7 M | $ 1.32 | 1.09 % | $ 115 M | USA |
 |
Amryt Pharma plc
AMYT
|
-38.6 M | - | - | $ 621 M | Britain |
 |
Cerus Corporation
CERS
|
-8.68 M | $ 2.62 | 0.38 % | $ 499 M | USA |
 |
G1 Therapeutics
GTHX
|
-39.5 M | - | - | $ 370 M | USA |
 |
Coherus BioSciences
CHRS
|
-181 M | $ 1.13 | 0.43 % | $ 132 M | USA |
 |
Celldex Therapeutics
CLDX
|
-287 M | $ 31.1 | 1.16 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-11.5 M | $ 4.25 | 3.16 % | $ 51.9 M | Israel |
 |
Cellectar Biosciences
CLRB
|
-23 M | $ 1.8 | 0.72 % | $ 4.69 M | USA |
 |
AbbVie
ABBV
|
15.1 B | $ 264.34 | 0.09 % | $ 468 B | USA |
 |
Humanigen
HGEN
|
-68.3 M | - | -81.12 % | $ 4.28 M | USA |
 |
Cocrystal Pharma
COCP
|
-9.02 M | $ 1.17 | 1.74 % | $ 13.2 M | USA |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 12.7 | 0.4 % | $ 3.79 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
-89.4 M | $ 5.4 | 2.65 % | $ 286 M | USA |
 |
Collegium Pharmaceutical
COLL
|
60.8 M | $ 22.53 | 0.2 % | $ 713 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
44.8 M | $ 116.1 | 4.93 % | $ 12.1 B | USA |
 |
IGM Biosciences
IGMS
|
-209 M | - | - | $ 76.9 M | USA |
 |
Kinnate Biopharma
KNTE
|
-121 M | - | - | $ 123 M | USA |
 |
Cardiff Oncology
CRDF
|
-49 M | $ 1.24 | 0.74 % | $ 82.9 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-85.3 M | $ 7.14 | 0.19 % | $ 95.1 M | USA |
 |
Karuna Therapeutics
KRTX
|
-495 M | - | - | $ 12.2 B | USA |
 |
Curis
CRIS
|
-5.71 M | $ 0.83 | 1.1 % | $ 10.9 M | USA |
 |
CorMedix
CRMD
|
150 M | $ 7.85 | 1.03 % | $ 565 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-517 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-665 M | $ 54.23 | 0.23 % | $ 4.88 B |  Schweiz |
|
Champions Oncology
CSBR
|
-1.14 M | $ 4.9 | 0.1 % | $ 67.8 M | USA |
 |
Chimerix
CMRX
|
-96.6 M | - | - | $ 756 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-43 M | $ 11.62 | 8.21 % | $ 918 M | USA |
 |
Cue Biopharma
CUE
|
-26.6 M | $ 31.41 | 1.45 % | $ 2.98 B | USA |
 |
CEL-SCI Corporation
CVM
|
-24.8 M | $ 1.67 | 2.38 % | $ 13.4 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-38.2 M | $ 4.85 | 0.2 % | $ 929 M | Canada |
 |
Cytokinetics, Incorporated
CYTK
|
-612 M | $ 64.66 | 0.17 % | $ 7.77 M | USA |
 |
Daré Bioscience
DARE
|
-13.6 M | $ 0.78 | 4.73 % | $ 8.72 M | USA |
 |
Adagene
ADAG
|
-21.4 M | $ 2.93 | 2.86 % | $ 173 M |  China |
 |
DiaMedica Therapeutics
DMAC
|
-34.4 M | $ 7.94 | 1.4 % | $ 373 M | USA |